Status:
COMPLETED
Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD
Lead Sponsor:
Queen's University
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
COPD
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
Preliminary information from our laboratory indicated that even patients with milder chronic obstructive pulmonary disease (COPD) can have significant physiological derangements which become more pron...
Eligibility Criteria
Inclusion
- Stable moderate COPD
- Post-bronchodilator FEV1/FVC\<0.7 and 50%≤FEV1\<80% predicted
- Baseline Dyspnea Index ≤ 9 and MRC dyspnea scale \>2
- Cigarette smoking history at least 20 pack-years
Exclusion
- Presence of a significant disease other than COPD that could contribute to dyspnea and exercise limitation
- Important contraindications to clinical exercise testing
- Use of daytime oxygen
- History of asthma
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT01491802
Start Date
January 1 2012
End Date
September 1 2014
Last Update
August 15 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Respiratory Investigation Unit at Kingston General Hospital
Kingston, Ontario, Canada, K7L 2V7